Jiancong Hu

Jiancong Hu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2019 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
QZQian Zhang
Qian Zhang
RLRui-Xian Liu
Rui-Xian Liu
KCKa-Wo Chan
Ka-Wo Chan
JHJiancong Hu
Jiancong Hu
JZJingdan Zhang
Jingdan Zhang
HLHuanliang Liu
Huanliang Liu
Acquired resistance remains a limitation of the clinical use of 5-fluorouracil (5-FU). Because exosomes, are important vesicles participating in intercellular communication, their contribution to the development of acquired 5-FU resistance needs to be elucidated. In this study, we aimed to examine the underlying mechanisms of exosomes from 5-FU resistant cells (RKO/R) in sustaining acquired 5-FU resistance in sensitive cells (RKO/P). Exosomes from a 5-FU-resistant cell line (RKO/R) and its parental cell line RKO/P were isolated and co-cultured with 5-FU-sensitive cells. Real-time cellular analysis (RTCA) and FACS analysis were used to examine cell viability and apoptosis. Exosomal protein profiling was performed using shotgun proteomics. Inhibitors and siRNAs were applied to study the involvement of selected proteins in 5-FU resistance. The effect of exosomal p-STAT3 (Tyr705) on the caspase cascade was examined by western blotting (WB) and high content analysis. Xenograft models were established to determine whether exosomal p-STAT3 can induce 5-FU resistance in vivo. Our results indicated that exosomes from RKO/R cells significantly promoted cell survival during 5-FU treatment. Proteomics and WB analysis results indicated that GSTP1 and p-STAT3 (Tyr705) were enriched in exosomes from RKO/R cells. Inhibition of p-STAT3 re-sensitized RKO/P cells to 5-FU via caspase cascade. Furthermore, p-STAT3 packaged by exosomes from RKO/R cells increased resistance of tumor cells to 5-FU in vivo. Our results reveal a novel mechanism by which p-STAT3-containing exosomes contribute to acquired 5-FU resistance in CRC. This study suggests a new option for potentiating the 5-FU response and finding biomarkers for chemotherapy resistance.

21 July 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JZJiawei Zhang
Jiawei Zhang
JDJiaxin Deng
Jiaxin Deng
JHJiancong Hu
Jiancong Hu
QZQinghua Zhong
Qinghua Zhong
JLJuan Li
Juan Li
Xuefeng GuoXuefeng Guo
Xuefeng Guo
Background: For colorectal cancer, preoperative (neoadjuvant) chemotherapy is more effective than postoperative chemotherapy because it not only eradicates micrometastases more effectively but also reduces the risk of incomplete intraoperative resection and tumor cell shedding. For the treatment of acute left-sided malignant colorectal obstruction, colorectal stents as well as stoma are being used to relieve the obstructive colorectal cancer, and as a bridge to surgery, allowing easy mobilization and resection of the colon. Neoadjuvant chemotherapy combined with self-expandable metal stents (SEMS) or neoadjuvant chemotherapy combined with decompressing stoma (DS) can be used as a bridge to elective surgery (BTS) as an alternative to emergency surgery in patients with acute left-sided malignant colorectal obstruction, but its benefit is uncertain. The purpose of this study was to evaluate the safety and feasibility of neoadjuvant chemotherapy as a bridge to surgery in the treatment of acute left-sided malignant colorectal obstruction. Methods: Data from patients who were admitted with acute left-sided malignant colorectal obstruction between January 2012 and December 2020 were retrospectively reviewed, and patients with gastrointestinal perforation or peritonitis were excluded. We performed one-to-two propensity score matching to compare the stoma requirement, postoperative complications, and other short-term oncological outcomes between the neoadjuvant chemotherapy group and surgery group. Results: There were no differences in intraoperative blood loss, operative time, one-year postoperative mortality, and postoperative tumor markers between the two groups. The 1-year recurrence-free survival (RFS) rates of neoadjuvant chemotherapy group and surgery group were 96.8 and 91.3% (p = 0.562). The neoadjuvant chemotherapy group was able to reduce stoma rate 1 year after surgery (p = 0.047). Besides, the neoadjuvant group significantly reduced postoperative bowel function time (p < 0.001), postoperative hospital stay (p < 0.001), total hospital stay (p = 0.002), postoperative complications (p = 0.017), reduction in need to stay in the intensive care unit (ICU) (p = 0.042). Conclusions: Neoadjuvant chemotherapy as a bridge to elective surgery in patients with acute left-sided malignant colorectal obstruction is safe and has many advantages. Prospective multicenter studies with large samples are needed to further evaluate the feasibility of neoadjuvant chemotherapy.

15 September 2025 in Cancer Research
Verified
Journal Article
Open access
CLChen Liu
Chen Liu
PLPeng Lai
Peng Lai
JHJiancong Hu
Jiancong Hu
SYShengmei Yin
Shengmei Yin
SGShuang Guo
Shuang Guo
ZHZhen He
Zhen He
High-fat diet (HFD) is positively correlated with colorectal cancer, but there are notable interindividual differences in susceptibility to the tumor-promoting effects of HFD. A better understanding of the mechanisms that modulate the outcomes of HFD could help inform precision prevention strategies for colorectal cancer. In this study, we found a key role for the gut microbiota in the individual differences observed in the tumor-promoting effects of HFD. Analysis of the gut bacteria enriched in mice resistant to HFD-induced cancer identified Lactobacillus johnsonii as an effective protector. Colonization of L. johnsonii increased intestinal chenodeoxycholic acid (CDCA) concentrations in HFD-exposed mice, which decelerated HFD-induced colorectal cancer progression. Mechanistically, L. johnsonii converted conjugated bile acid to CDCA via bile salt hydrolase, and CDCA induced mitochondrial dysfunction and oxidative stress to promote apoptosis, effectively suppressing tumor development. These results establish the gut microbiota as a mediator of interindividual differences in cancer susceptibility induced by HFD and reveal a probiotic strategy with the ability to inhibit tumorigenesis, suggesting a possible route to reduce HFD-induced colorectal cancer progression. Significance: Investigation of bacteria–host interactions that alter cancer susceptibility uncovers suppression of high-fat diet–induced colorectal cancer by Lactobacillus johnsonii, offering a translational approach to improve cancer prevention. See related commentary by Dalal and Shah, p. 4579

8 October 2021 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
DLDezheng Lin
Dezheng Lin
WLWei Liu
Wei Liu
ZCZexian M.D. Chen
Zexian M.D. Chen
XHXiaowen M.D. He
Xiaowen M.D. He
ZZZheyu Zheng
Zheyu Zheng
JHJiancong Hu
Jiancong Hu
BACKGROUND: Postoperative benign anastomotic stricture is associated with colorectal anastomosis following surgery for colorectal cancer. Endoscopic stricturotomy is a novel technique that has been demonstrated to be safe and effective for the treatment of colorectal anastomotic stricture in several case reports and series. OBJECTIVE: We designed this study to investigate the efficacy of endoscopic stricturotomy for postoperative benign anastomotic stricture in patients for colorectal cancer. The primary outcomes were stricture-recurrence–free survival and reoperation-free survival. DESIGN: This is a retrospective study. SETTING: This study presents a single-center experience. PATIENTS: This retrospective study included patients with colorectal cancer who underwent surgical resection and developed anastomotic stricture between January 2014 and June 2019 and were treated with endoscopic stricturotomy. MAIN OUTCOME MEASURES: Immediate technical success of endoscopic stricturotomy and the factors associated with success and recurrence were investigated. RESULTS: Endoscopic stricturotomy was performed in 57 patients, and immediate technical success was achieved in 84% of the patients. The mean follow-up was 31.3 (15.8) months (range, 9–74 months). Postoperative benign anastomotic stricture recurred in 11 patients after initial successful endoscopic stricturotomy; 10 of the 11 recurrent patients accepted reoperation. Univariate and multivariate analysis indicated that length of stricture ≥1 cm was an independent risk factor for failure of the initial endoscopic stricturotomy (OR, 9.423; 95% CI, 1.729–51.350; p = 0.010) and the recurrence of postoperative benign anastomotic stricture after the initial endoscopic stricturotomy (OR, 13.521; 95% CI, 2.305–79.306; p = 0.004). LIMITATIONS: The study was limited by its small sample size and retrospective design. CONCLUSIONS: Endoscopic stricturotomy is a safe and effective technique for postoperative benign anastomotic stricture. However, if the length of the stricture is ≥1 cm, endoscopic stricturotomy may not be effective, and recurrence of postoperative benign anastomotic stricture is also likely. See Video Abstract at http://links.lww.com/DCR/B739. ESTRICTUROTOMÍA ENDOSCÓPICA PARA PACIENTES CON ESTRICCIÓN ANASTOMÓTICA BENIGNA POSTOPERATORIA PARA EL CÁNCER COLORRECTAL: ANTECEDENTES: La estenosis anastomótica benigna postoperatoria se asocia con anastomosis colorrectal después de la cirugía para el cáncer colorrectal. La estricturotomia endoscópica es una técnica novedosa que se ha demostrado que es segura y efectiva para el tratamiento de la estenosis anastomótica colorrectal en varios informes de casos o series. OBJETIVO: Diseñamos este estudio para investigar la eficacia de la estricturotomia endoscópica para la estenosis anastomótica benigna postoperatoria en pacientes con cáncer colorrectal. El resultado primario fue la supervivencia libre de restricción estricta y la supervivencia libre de reoperación. DISEÑO: Este es un estudio retrospectivo. CONFIGURACIÓN: Este estudio presenta una experiencia de un solo centro. PACIENTES: Este estudio retrospectivo incluyó pacientes con cáncer colorrectal que se sometieron a resección quirúrgica y desarrollaron estenosis anastomótica entre enero de 2014 y junio de 2019 y tratados con estricturotomia endoscópica. MEDIDAS PRINCIPALES DE RESULTADO: Éxito técnico inmediato y estenosurotomía endoscópica, los factores asociados con el éxito y la recurrencia. RESULTADOS: Se realizó estricturotomia endoscópica en 57 pacientes, y se logró un éxito técnico inmediato en el 84% de los pacientes. El seguimiento medio fue de 31,3 (15,8) meses (rango, 9 a 74 meses), el POBAS se repitió en 11 pacientes después del éxito inicial de ESt. 10 de los 11 pacientes recurrentes aceptaron la reoperación. El análisis univariado y multivariado indicó que la longitud de la estenosis ≥1 cm era un factor de riesgo independiente para el fracaso de la estricturotomia endoscópica inicial (odds ratio = 9,423; IC del 95% = 1.729–51.350; p = 0.010) y la recurrencia de estenosis anastomótica benigna postoperatoria después de la estricturotomia endoscópica inicial (odds ratio = 13,521; IC del 95% = 2,305–79,306; p = 0.004). LIMITACIONES: El estudio estuvo limitado por su pequeño tamaño de muestra y diseño retrospectivo. CONCLUSIONES: La estricturotomia endoscópica es una técnica segura y efectiva para la estructura anastomótica benigna postoperatoria. Sin embargo, si la longitud de la estenosis es ≥1 cm, la estricturotomia endoscópica puede no ser efectiva y también es probable que se repita la estenosis anastomótica benigna postoperatoria. Consulte Video Resumen en http://links.lww.com/DCR/B739.

8 October 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YLYi Lu
Yi Lu
JWJialin Wu
Jialin Wu
TYTao Yang
Tao Yang
LLLei Lian
Lei Lian
HYHonho Yu
Honho Yu
JHJiancong Hu
Jiancong Hu
Early-onset gastric cancer (EOGC) is a distinct clinical entity with unique epidemiological and pathological features. Despite an overall decline in GC incidence in many regions, recent studies have shown an increasing trend in EOGC incidence in some areas. This study aims to systematically evaluate the global, regional, and national burden of EOGC from 1990 to 2021 using data from the Global Burden of Disease (GBD) 2021 study. Data on the incidence, mortality, and disability-adjusted life-years (DALYs) of EOGC were obtained from the GBD 2021 database. The age-standardized incidence rates (ASIRs), age-standardized mortality rates (ASMRs), and age-standardized DALYs rates (ASDRs) were calculated. Estimated annual percentage change (EAPC) was used to assess temporal trends. The Bayesian age-period-cohort model was employed to project trends up to 2035. Globally, the ASIR of EOGC decreased from 5.40 per 100,000 in 1990 to 3.17 per 100,000 in 2021 (EAPC -1.8, 95% CI: -1.9 to -1.7). The ASMR decreased from 2.00 per 100,000 in 1990 to 1.31 per 100,000 in 2021 (EAPC -2.4, 95% CI: -2.5 to -2.3), and the ASDR decreased from 97.73 per 100,000 in 1990 to 63.98 per 100,000 in 2021 (EAPC -2.5, 95% CI:-2.6 to -2.4). East Asia had the highest ASIR, ASMR, and ASDR. Regions with higher Socio-demographic Index (SDI) values experienced more significant declines in EOGC incidence and mortality. High-sodium diets and smoking were identified as significant risk factors. Forecasts toward 2035 indicate a continued decline in ASIR, ASMR, and ASDR globally. Despite a decrease in ASIR, ASMR, and ASDR globally, the absolute burden of EOGC remains high, with significant regional disparities. Targeted prevention and treatment strategies are needed, particularly in low- and middle-income countries. Future research should focus on identifying additional risk factors and exploring the effectiveness of different preventive strategies in various regions.

15 June 2022 in International Journal of Colorectal Disease
Verified
Journal Article
Open access
PDF file
XCXijie Chen
Xijie Chen
WWWenhui Wang
Wenhui Wang
JCJunguo Chen
Junguo Chen
LXLiang Xu
Liang Xu
XHXiaosheng He
Xiaosheng He
SYShi Yin
Shi Yin
Purpose: Watch and wait strategy is a safe and effective alternative to surgery in patients with locally advanced rectal cancer (LARC) who have achieved pathological complete response (pCR) after neoadjuvant therapy (NAT); present restaging methods do not meet clinical needs. This study aimed to construct a machine learning (ML) model to predict pCR preoperatively. Methods: LARC patients who received NAT were included to generate an extreme gradient boosting-based ML model to predict pCR. The group was divided into a training set and a tuning set at a 7:3 ratio. The SHapley Additive exPlanations value was used to quantify feature importance. The ML model was compared with a nomogram model developed using independent risk factors identified by conventional multivariate logistic regression analysis. Results: Compared with the nomogram model, our ML model improved the area under the receiver operating characteristics from 0.72 to 0.95, sensitivity from 43 to 82.2%, and specificity from 87.1 to 91.6% in the training set, the same trend applied to the tuning set. Neoadjuvant radiotherapy, preoperative carbohydrate antigen 125 (CA125), CA199, carcinoembryonic antigen level, and depth of tumor invasion were significant in predicting pCR in both models. Conclusion: Our ML model is a potential alternative to the existing assessment tools to conduct triage treatment for patients and provides reference for clinicians in tailoring individual treatment: the watch and wait strategy is used to avoid surgical trauma in pCR patients, and non-pCR patients receive surgical treatment to avoid missing the optimal operation time window.